Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 [Yahoo! Finance]
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Guggenheim from $13.00 to $14.00. They now have a "buy" rating on the stock.